Calidi BiotherapeuticsCLDI -5.88%12 EV-to-EBITDA is 0.10 as of Jul. 12, 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 391 Biotechnology companies, Calidi Biotherapeutics ranks better than 95.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Calidi Biotherapeutics's enterprise value is $-1.65 Mil.
Calidi Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-17.24 Mil. Therefore, Calidi Biotherapeutics's EV-to-EBITDA for today is 0.10.
The historical rank and industry rank for Calidi Biotherapeutics's EV-to-EBITDA or its related term are showing as below:
CLDI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.1
Current: 0.1
During the past 6 years, the highest EV-to-EBITDA of Calidi Biotherapeutics was 0.10. The lowest was 0.00. And the median was 0.00.
CLDI's EV-to-EBITDA is ranked better than 95.4% of 391
companies
in the Biotechnology industry
Industry Median: 13.14
vs CLDI: 0.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Calidi Biotherapeutics's PE Ratio (TTM) for today is calculated as:
Calidi Biotherapeutics's share price for today is $0.1409.
Calidi Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.192.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Calidi Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Calidi Biotherapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Calidi Biotherapeutics's EV-to-EBITDA falls into.
Calidi Biotherapeutics's current Enterprise Value is $-1.65 Mil.
Calidi Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Calidi Biotherapeutics (CLDI) has a EV-to-EBITDA of 0.10 as of Jul. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Calidi Biotherapeutics. According to the industry distribution chart, Calidi Biotherapeutics ranks #18 out of 391 companies in the Biotechnology industry, placing it in the top 4.6%.
Is Calidi Biotherapeutics' EV-to-EBITDA too high?
Calidi Biotherapeutics' current EV-to-EBITDA is 0.10. The Biotechnology industry median EV-to-EBITDA is 13.14. Calidi Biotherapeutics' value of 0.10 is 99.2% below this industry median. Based on the distribution chart, Calidi Biotherapeutics ranks #18 out of 391 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' EV-to-EBITDA compare to DCOY and CDT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #18 out of 391 companies for EV-to-EBITDA. This places Calidi Biotherapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.14. Calidi Biotherapeutics' value of 0.10 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.14, based on 391 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Calidi Biotherapeutics's current EV-to-EBITDA of 0.10 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Calidi Biotherapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Calidi Biotherapeutics's current EV-to-EBITDA is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current EV-to-EBITDA of 0.10. The current EV-to-EBITDA is 0.10 and 99.2% below the Biotechnology industry median of 13.14. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current EV-to-EBITDA is 0.10 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score
Get the complete analysis for CLDI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLDI has been successfully added to your 
